These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

461 related items for PubMed ID: 31370808

  • 1. Clinical application of a contingent screening strategy for trisomies with cell-free DNA: a pilot study.
    Sánchez-Durán MÁ, Bernabeu García A, Calero I, Ramis Fossas J, Illescas T, Avilés MT, Maiz N, Carreras E.
    BMC Pregnancy Childbirth; 2019 Aug 01; 19(1):274. PubMed ID: 31370808
    [Abstract] [Full Text] [Related]

  • 2. Routine first-trimester screening for fetal trisomies in twin pregnancy: cell-free DNA test contingent on results from combined test.
    Galeva S, Konstantinidou L, Gil MM, Akolekar R, Nicolaides KH.
    Ultrasound Obstet Gynecol; 2019 Feb 01; 53(2):208-213. PubMed ID: 30353581
    [Abstract] [Full Text] [Related]

  • 3. Clinical implementation of routine screening for fetal trisomies in the UK NHS: cell-free DNA test contingent on results from first-trimester combined test.
    Gil MM, Revello R, Poon LC, Akolekar R, Nicolaides KH.
    Ultrasound Obstet Gynecol; 2016 Jan 01; 47(1):45-52. PubMed ID: 26498918
    [Abstract] [Full Text] [Related]

  • 4. Contingent first-trimester screening for aneuploidies with cell-free DNA in a Danish clinical setting.
    Miltoft CB, Rode L, Ekelund CK, Sundberg K, Kjaergaard S, Zingenberg H, Tabor A.
    Ultrasound Obstet Gynecol; 2018 Apr 01; 51(4):470-479. PubMed ID: 28640470
    [Abstract] [Full Text] [Related]

  • 5. Noninvasive prenatal screening in twin pregnancies with cell-free DNA using the IONA test: a prospective multicenter study.
    Khalil A, Archer R, Hutchinson V, Mousa HA, Johnstone ED, Cameron MJ, Cohen KE, Ioannou C, Kelly B, Reed K, Hulme R, Papageorghiou AT.
    Am J Obstet Gynecol; 2021 Jul 01; 225(1):79.e1-79.e13. PubMed ID: 33460583
    [Abstract] [Full Text] [Related]

  • 6. Contingent cfDNA Screening Implementation: Increasing Diagnostic Accuracy and Reducing Invasive Testing - 6 Years' Results in a Single Center.
    Cubo AM, Huélamo M, Martín-Seisdedos MC, Hernández-Hernández E, Lapresa-Alcalde MV, Rodríguez-Martín MO, Doyague MJ, Sayagués JM.
    Fetal Diagn Ther; 2022 Jul 01; 49(3):103-113. PubMed ID: 35259749
    [Abstract] [Full Text] [Related]

  • 7. Prenatal screening for trisomy 21: a comparative performance and cost analysis of different screening strategies.
    Huang T, Gibbons C, Rashid S, Priston MK, Bedford HM, Mak-Tam E, Meschino WS.
    BMC Pregnancy Childbirth; 2020 Nov 23; 20(1):713. PubMed ID: 33228595
    [Abstract] [Full Text] [Related]

  • 8. Performance of cell-free DNA testing for common fetal trisomies in triplet pregnancies.
    Zakaria H, Kleinfinger P, Lohmann L, Costa JM, Tsatsaris V, Salomon LJ, Jouannic JM, Rosenblatt J, Demain A, Benachi A, El Khattabi L, Vivanti AJ.
    Prenat Diagn; 2024 May 23; 44(5):555-561. PubMed ID: 38448008
    [Abstract] [Full Text] [Related]

  • 9. Cell-free fetal DNA analysis in maternal plasma as screening test for trisomies 21, 18 and 13 in twin pregnancy.
    Le Conte G, Letourneau A, Jani J, Kleinfinger P, Lohmann L, Costa JM, Benachi A.
    Ultrasound Obstet Gynecol; 2018 Sep 23; 52(3):318-324. PubMed ID: 28833712
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The value of combined detailed first-trimester ultrasound-biochemical analysis for screening fetal aneuploidy in the era of non-invasive prenatal testing.
    Ye C, Duan H, Liu M, Liu J, Xiang J, Yin Y, Zhou Q, Yang D, Yan R, Li R.
    Arch Gynecol Obstet; 2024 Aug 23; 310(2):843-853. PubMed ID: 37938359
    [Abstract] [Full Text] [Related]

  • 13. Prenatal screening for fetal aneuploidy in singleton pregnancies.
    Chitayat D, Langlois S, Douglas Wilson R, SOGC GENETICS COMMITTEE, CCMG PRENATAL DIAGNOSIS COMMITTEE.
    J Obstet Gynaecol Can; 2011 Jul 23; 33(7):736-750. PubMed ID: 21749752
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Screening for trisomies by cell-free DNA testing of maternal blood: consequences of a failed result.
    Revello R, Sarno L, Ispas A, Akolekar R, Nicolaides KH.
    Ultrasound Obstet Gynecol; 2016 Jun 23; 47(6):698-704. PubMed ID: 26743020
    [Abstract] [Full Text] [Related]

  • 17. False-positive rates in screening for trisomies 18 and 13: a comparison between first-trimester combined screening and a cfDNA-based approach.
    Kagan KO, Sonek J, Sroka A, Abele H, Wagner P, Prodan N, Hoopmann M.
    Arch Gynecol Obstet; 2019 Feb 23; 299(2):431-437. PubMed ID: 30519751
    [Abstract] [Full Text] [Related]

  • 18. UK NHS pilot study on cell-free DNA testing in screening for fetal trisomies: factors affecting uptake.
    Gil MM, Giunta G, Macalli EA, Poon LC, Nicolaides KH.
    Ultrasound Obstet Gynecol; 2015 Jan 23; 45(1):67-73. PubMed ID: 25302655
    [Abstract] [Full Text] [Related]

  • 19. First-trimester contingent screening for trisomies 21, 18 and 13 by biomarkers and maternal blood cell-free DNA testing.
    Nicolaides KH, Syngelaki A, Poon LC, Gil MM, Wright D.
    Fetal Diagn Ther; 2014 Jan 23; 35(3):185-92. PubMed ID: 24192489
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.